New drug combo tested for Tough-to-Treat breast cancer
NCT ID NCT04572295
Summary
This early-stage study is testing the safety of an experimental drug called E7090, both alone and combined with other cancer medications. It involves 51 women with advanced, hormone-sensitive breast cancer that has returned or spread. The main goal is to find safe dosage levels and understand side effects before larger studies can begin.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eisai Trial Site 1
Koto-ku, Tokyo, Japan
-
Eisai Trial Site 10
Kitaadachi-gun, Saitama, Japan
-
Eisai Trial Site 11
Nagoya, Aichi-ken, Japan
-
Eisai Trial Site 2
Shinagawa-ku, Tokyo, Japan
-
Eisai Trial Site 3
Chuo-ku, Tokyo, Japan
-
Eisai Trial Site 4
Sendai, Miyagi, Japan
-
Eisai Trial Site 5
Yokohama, Kanagawa, Japan
-
Eisai Trial Site 6
Kashiwa, Chiba, Japan
-
Eisai Trial Site 7
Chuo-ku, Osaka, Japan
-
Eisai Trial Site 8
Shinjuku-ku, Tokyo, Japan
-
Eisai Trial Site 9
Matsuyama, Ehime, Japan
Conditions
Explore the condition pages connected to this study.